Covid-19 roundup: Mod­er­na says vac­cine pro­duces 'strong' re­sponse in 5- to 11-year-olds; As­pen Phar­ma­care plans to up vac­cine pro­duc­tion in South Africa — re­port

Af­ter see­ing a “ro­bust” im­mune re­sponse in 6- to 11-year-olds dosed with its Covid-19 vac­cine, Mod­er­na says it’s head­ed to the FDA.

The re­sults came from the Phase II/III Kid­COVE study, which en­rolled 4,753 par­tic­i­pants be­tween the ages of 6 and un­der 12 years old. The kids were giv­en two half-dos­es of the Mod­er­na vac­cine (50 µg each), and showed “strong im­mune re­sponse” a month af­ter the sec­ond dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER